OS Therapies Incorporated (OSTX) AI Stock Analysis

• Market Cap: $65.15M
• Dividend Yield: N/A
• Average Volume (3M): 448.36K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.28
• Revenue Growth: N/A
• EPS Growth: -75.62%
• Country: US
• Employees: 4
• Sector: Healthcare
• Sector Strength: 49
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 31,624,077
• 10 Day Avg. Volume: 634,705
• 30 Day Avg. Volume: 448,356
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.53
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -5.06
• 1Y Price Target: $12.50
• Price Target Upside: 506.80% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 27 Underperform
• Price Target: ―

OS Therapies Incorporated faces significant financial difficulties, marked by increasing net losses, negative cash flows, and reliance on external financing. The technical analysis indicates bearish momentum with the stock trading below its moving averages. Valuation is challenging with no earnings to support a P/E ratio or dividend yield. These factors contribute to a low overall stock score, reflecting the company's financial instability and negative market sentiment.

Positive Factors

Clinical Trial Success

Positive updated interim 2-year overall survival data from the P2b trial showed 66.6% of OST-HER2 treated patients achieved survival compared to 40% for historical control.

Regulatory Advancement

The company continues to make progress toward a potential rolling BLA filing, including an End-of-Phase 2 meeting with FDA scheduled, which suggests a favorable outlook for accelerated approval.

Negative Factors

Financial Performance

OS Therapies reported a net loss of ($3.8M) and ended the period with $3.1M in cash, indicating a need to raise additional capital in the near-term.

OS Therapies Incorporated Business Overview & Revenue Model

Company Description

OS Therapies Incorporated (OSTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of cancer and other serious diseases. The company operates within the healthcare sector, with a strong emphasis on oncology research and development. Its core products and services include the creation of targeted therapies designed to improve patient outcomes and quality of life through advanced scientific approaches.

How the Company Makes Money

OS Therapies Incorporated generates revenue primarily through the commercialization of its proprietary therapies once they receive regulatory approval. The company engages in strategic partnerships and licensing agreements with larger pharmaceutical companies to co-develop and market its treatments, thereby earning revenue through upfront payments, milestone achievements, and royalties on sales. Additionally, OS Therapies may receive funding through grants and research collaborations with academic institutions and government agencies, which support its ongoing research and development efforts.

OS Therapies Incorporated Financial Statement Overview

Summary

OS Therapies Incorporated is experiencing significant financial challenges, characterized by a lack of revenue, increasing net losses, and negative operating cash flows. While there is a notable improvement in equity position and liquidity in 2024, the financial stability remains weak due to past leverage and ongoing operational losses. The company's reliance on external financing to sustain operations suggests potential risks if future fundraising efforts do not meet cash requirements.

Income Statement

OS Therapies Incorporated has reported no revenue for the past several years, indicating no income generation from operations. The company has consistently incurred significant net losses, with an increasing trend in net losses from -7.42 million USD in 2021 to -8.88 billion USD in 2024. This trend suggests a lack of profitability and potential challenges in revenue generation and cost management.

Balance Sheet

The company's balance sheet shows high cash reserves of 5.53 billion USD in 2024, indicating strong liquidity. However, the equity is negative in prior years, but significantly positive in 2024 at 6.05 billion USD, suggesting a recent capital injection or debt restructuring. The absence of total debt in 2024 improves the debt-to-equity ratio, though previous years show very high leverage with negative equity, indicating financial instability and potential risk in managing liabilities.

Cash Flow

Operating cash flows are consistently negative, reflecting ongoing cash usage in operations without any revenue inflow. The free cash flow has worsened from -3.79 million USD in 2022 to -7.28 billion USD in 2024, indicating increasing operational cash demands. Positive financing cash flow in 2024 suggests reliance on external financing to support cash needs, highlighting a potential risk if financing sources become restricted.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	-4.25K
EBITDA	-6.81B	-4.34M	-4.45M	-4.84M	―
Net Income	-8.88B	-7.79M	-6.25M	-7.42M	―
Balance Sheet
Total Assets	5.54M	798.08K	509.11K	325.89K	1.68M
Cash, Cash Equivalents and Short-Term Investments	5.53M	38.98K	171.48K	80.79K	1.23M
Total Debt	0.00	14.61M	10.35M	7.07M	5.90M
Total Liabilities	4.73M	24.81M	18.07M	11.78M	8.00M
Stockholders Equity	6.05B	-24.02M	-17.56M	-11.45M	-6.33M
Cash Flow
Free Cash Flow	-7.28M	-3.01M	-3.79M	-4.41M	-2.42M
Operating Cash Flow	-7.28M	-3.01M	-3.79M	-4.40M	-2.41M
Investing Cash Flow	0.00	1.15K	230.88K	200.47K	158.29K
Financing Cash Flow	12.78B	2.87M	3.65M	3.05M	3.48M

OS Therapies Incorporated Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.46B	-0.16	-46.00%	2.25%	22.82%	-2.28%
BDRX	45 Neutral	$470.69K	―	-89.21%	―	-100.00%	96.37%
VRPX	31 Underperform	$13.67K	―	-2364.82%	―	―	60.26%
SLRX	30 Underperform	$3.51M	―	-660.37%	―	―	74.27%
ZVSA	29 Underperform	$1.25M	―	-112.65%	―	―	93.34%
OSTX	27 Underperform	$65.15M	―		―	―	-75.62%